Neoadjuvant Sacituzumab Govitecan Plus Pembrolizumab in Resectable Non-Small Cell Lung Cancer
Conditions: Lung Cancer Interventions: Drug: Sacituzumab Govitecan; Drug: Pembrolizumab Sponsors: Chinese University of Hong Kong Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | China Health | Hong Kong Health | Lung Cancer | Neoadjuvant Therapy | Non-Small Cell Lung Cancer | Research